| abstract |
The present invention generally provides a method of reducing B-cells in an individual using CD37-specific binding molecules. In particular, the present invention utilizes a CD37-specific binding molecule alone, or a combination of a CD37-specific binding molecule and a CD20-specific binding molecule (and thus sometimes has a synergistic effect) to treat B-cells. It provides a method of reducing. The invention also provides agents and methods for the treatment of diseases associated with aberrant B-cell activity. |